Retour

Cellectis publie ses résultats financiers du quatrième trimestre 2023 et de l’exercice 2023 

Stocks Earnings Releases and Operating Results

•   Présentation de données préliminaires de l’essai clinique NATHALI-01 et de résultats cliniques actualisés de l’essai BALLI-01 lors de la réunion annuelle de l’American Society of Hematology (ASH)

GlobeNewswire Inc. • 29/04/2024 à 22:46:00
Cellectis S.A. American Depositary Shares
Website: https://www.cellectis.com
Status: Active
Company Info

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

List Date2015-03-25
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeADRC
Currency NameUSD
CIK0001627281
Composite figiBBG0084L1XN2
Share Class figiBBG0084L1YD1
Market Cap220,183,937 USD
Total Employees216
Share Class Shares Outstanding71750000
Weighted Shares Outstanding71955535
Round Lot100
Updated date2024-05-12
Stats
Last 5 days
15-05
14-05
13-05
10-05
9-05
Last
3.19
3.035
3.12
3.059
3.27
Variance
4.93%
-2.72%
2.43%
-5.67%
6.07%
Open
3.04
3.12
3.046
3.243
3.083
Highest
3.19
3.12
3.12
3.243
3.3
Lowest
3.186
3.12
3.07
3.225
3.3
History
PeriodVarhighestlowest
1 week
-1.72%
3.3
3.07
1 month
21.15%
2.649
2.557
3 month
6.32%
2.92
2.435
6 month
10.58%
2.74
2.435
1 year
78.24%
1.8198
0.962777
3 year
-80.4%
15.72
0.962777
5 year
-84.12%
19.3
0.962777
10 year
-92.7%
42.04
0.962777
Calendar
16 May 2024 (Time UTC) Actual Previous Consensus
16:30
United States
3331000000000.000
★★
16:30
United States
7353000000000.000
15:50
United States
★★
11:30
United States
11:30
United States
5.275
11:30
United States
5.270
11:30
United States
11:30
United States
★★
10:30
United States
10:30
United States
MAY 10
70000000000.000
79000000000.000
76000000000.000
10:30
United States
MAY 10
★★
10:00
United States
09:15
United States
APR
-0.300
0.200
0.100
★★
09:15
United States
APR
-0.380
0.090
09:15
United States
APR
78.400
78.500
78.400
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:CLLS240419P00005000 OPASPS Put American 100 5 EMLD 2024-04-19
O:CLLS240419P00002500 OPASPS Put American 100 2.5 EMLD 2024-04-19
O:CLLS240419C00007500 OCASPS Call American 100 7.5 EMLD 2024-04-19
O:CLLS240419C00005000 OCASPS Call American 100 5 EMLD 2024-04-19
O:CLLS240419C00002500 OCASPS Call American 100 2.5 EMLD 2024-04-19
O:CLLS240419P00007500 OPASPS Put American 100 7.5 EMLD 2024-04-19
O:CLLS240315P00007500 OPASPS Put American 100 7.5 EMLD 2024-03-15
O:CLLS240315P00005000 OPASPS Put American 100 5 EMLD 2024-03-15
O:CLLS240315P00002500 OPASPS Put American 100 2.5 EMLD 2024-03-15
O:CLLS240315C00007500 OCASPS Call American 100 7.5 EMLD 2024-03-15
O:CLLS240315C00005000 OCASPS Call American 100 5 EMLD 2024-03-15
O:CLLS240315C00002500 OCASPS Call American 100 2.5 EMLD 2024-03-15
O:CLLS240216P00007500 OPASPS Put American 100 7.5 EMLD 2024-02-16
O:CLLS240216P00005000 OPASPS Put American 100 5 EMLD 2024-02-16
O:CLLS240216P00002500 OPASPS Put American 100 2.5 EMLD 2024-02-16
O:CLLS240216C00007500 OCASPS Call American 100 7.5 EMLD 2024-02-16
O:CLLS240216C00005000 OCASPS Call American 100 5 EMLD 2024-02-16
O:CLLS240216C00002500 OCASPS Call American 100 2.5 EMLD 2024-02-16
O:CLLS240119P00007500 OPASPS Put American 100 7.5 EMLD 2024-01-19
O:CLLS240119P00005000 OPASPS Put American 100 5 EMLD 2024-01-19
O:CLLS240119P00002500 OPASPS Put American 100 2.5 EMLD 2024-01-19
O:CLLS240119C00007500 OCASPS Call American 100 7.5 EMLD 2024-01-19
O:CLLS240119C00005000 OCASPS Call American 100 5 EMLD 2024-01-19
O:CLLS240119C00002500 OCASPS Call American 100 2.5 EMLD 2024-01-19
O:CLLS231215P00007500 OPASPS Put American 100 7.5 EMLD 2023-12-15
O:CLLS231215P00005000 OPASPS Put American 100 5 EMLD 2023-12-15
O:CLLS231215P00002500 OPASPS Put American 100 2.5 EMLD 2023-12-15
O:CLLS231215C00007500 OCASPS Call American 100 7.5 EMLD 2023-12-15
O:CLLS231215C00005000 OCASPS Call American 100 5 EMLD 2023-12-15
O:CLLS231215C00002500 OCASPS Call American 100 2.5 EMLD 2023-12-15
O:CLLS231117P00007500 OPASPS Put American 100 7.5 EMLD 2023-11-17
O:CLLS231117P00005000 OPASPS Put American 100 5 EMLD 2023-11-17
O:CLLS231117P00002500 OPASPS Put American 100 2.5 EMLD 2023-11-17
O:CLLS231117C00007500 OCASPS Call American 100 7.5 EMLD 2023-11-17
O:CLLS231117C00005000 OCASPS Call American 100 5 EMLD 2023-11-17
O:CLLS231117C00002500 OCASPS Call American 100 2.5 EMLD 2023-11-17
O:CLLS231020P00007500 OPASPS Put American 100 7.5 EMLD 2023-10-20
O:CLLS231020P00005000 OPASPS Put American 100 5 EMLD 2023-10-20
O:CLLS231020P00002500 OPASPS Put American 100 2.5 EMLD 2023-10-20
O:CLLS231020C00007500 OCASPS Call American 100 7.5 EMLD 2023-10-20
O:CLLS231020C00005000 OCASPS Call American 100 5 EMLD 2023-10-20
O:CLLS231020C00002500 OCASPS Call American 100 2.5 EMLD 2023-10-20
O:CLLS230915P00007500 OPASPS Put American 100 7.5 EMLD 2023-09-15
O:CLLS230915P00005000 OPASPS Put American 100 5 EMLD 2023-09-15
O:CLLS230915P00002500 OPASPS Put American 100 2.5 EMLD 2023-09-15
O:CLLS230915C00007500 OCASPS Call American 100 7.5 EMLD 2023-09-15
O:CLLS230915C00005000 OCASPS Call American 100 5 EMLD 2023-09-15
O:CLLS230915C00002500 OCASPS Call American 100 2.5 EMLD 2023-09-15
O:CLLS230818P00007500 OPASPS Put American 100 7.5 EMLD 2023-08-18
O:CLLS230818P00005000 OPASPS Put American 100 5 EMLD 2023-08-18
O:CLLS230818P00002500 OPASPS Put American 100 2.5 EMLD 2023-08-18
O:CLLS230818C00007500 OCASPS Call American 100 7.5 EMLD 2023-08-18
O:CLLS230818C00005000 OCASPS Call American 100 5 EMLD 2023-08-18
O:CLLS230818C00002500 OCASPS Call American 100 2.5 EMLD 2023-08-18
News Stream
News Other News
(Article 223-16 of General Regulation of the French financial markets authority)
GlobeNewswire Inc. • 1w ago
News Other News
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)
GlobeNewswire Inc. • 1w ago
News Other News
NEW YORK, 06 mai 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a annoncé aujourd'hui, que, à la suite de de l'approbation du ministère français de l'économie et de la satisfaction des autres conditions suspensives, AstraZeneca (LSE/STO/Nasdaq : AZN) a réalisé l’investissement additionnel de 140 millions de dollars dans la Société tel que précédemment annoncé par Cellectis le 1er et le 15 novembre 2023 (l’ « Investissement Additionnel »).
GlobeNewswire Inc. • 1w ago
News Other News
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
GlobeNewswire Inc. • 1w ago
News Other News
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
GlobeNewswire Inc. • 1w ago
News Other News
NEW YORK, 02 mai 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) (la « Société »), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN® pour développer de potentielles thérapies innovantes pour le traitement de maladies graves, a annoncé aujourd'hui la démission de M. Bing Wang de son poste au sein de la Société avec effet immédiat, et la nomination concomitante de M. Arthur Stril en tant que directeur financier par intérim, en remplacement de M. Bing Wang.
GlobeNewswire Inc. • 1w ago
Stocks Earnings Releases and Operating Results
•   Présentation de données préliminaires de l’essai clinique NATHALI-01 et de résultats cliniques actualisés de l’essai BALLI-01 lors de la réunion annuelle de l’American Society of Hematology (ASH)
GlobeNewswire Inc. • 2w ago
Stocks Earnings Releases and Operating Results
•   Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting
GlobeNewswire Inc. • 2w ago
News Other News
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs at ASGCT 2024
GlobeNewswire Inc. • 3w ago
News Other News
NEW YORK, 22 avr. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN® pour développer de potentielles thérapies innovantes pour le traitement de maladies graves, présentera ses premières données préliminaires explorant de nouveaux procédés d'éditions par TALEN® dans les cellules souches et progénitrices hématopoïétiques (CSPHs) à l'American Society of Gene and Cell Therapy (ASGCT), qui se tiendra du 7 au 11 mai 2024.
GlobeNewswire Inc. • 3w ago
See All

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT